918博天堂(中华区)官方网站

Shanghai, China, January 21, 2021 --- Huaota is pleased to announce that HB0025 developed by the company has been approved and issued with the “Approval Notice for Drug Clinical Trial” by the National Medical Products Administration. It is the 2nd approval received by HB0025 and FDA's IND approval was granted in Dec 2020.

HB0025 is the first-in-class bispecific fusion protein targeting PD-L1/VEGF that has obtained clinical trial licenses in both China and the United States. Huaota expects to initiate the Phase I clinical study of HB0025 in the states in February and China will join the study in April, 2021